pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Drugs
by stage
  • Marketed
  • Phase 3
  • Phase 2
  • Phase 1
  • Preclinical
browse
  • Most catalysts
  • Recently active
  • All drugs →
  • Companies
  • Patent cliff
Calendar
what
  • Trial readouts
  • PDUFA dates
  • Approvals
  • Earnings
when
  • Upcoming
  • Month grid
  • Recently passed
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
  • Drugs
  • Calendar
  • Companies
Hubs
  • Topics
  • Patent cliff
  • Publications
  • Readouts
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
Fierce Biotech·5h ago·2 min read
save

Danaher teams up with Microsoft to boost ‘experimental execution’

Danaher Corporation and Microsoft are teaming for a strategic partnership to develop smart scientific instruments and an interoperable agentic ecosystem.

Nov 22, 2026·read at Fierce Biotech ↗

MedTech Danaher teams up with Microsoft to boost ‘experimental execution’ By Patrick McGuire Nov 22, 2026 2:44am Microsoft Danaher Corp Artificial Intelligence Diagnostics Danaher Corporation and Microsoft are teaming for a strategic partnership to develop smart scientific instruments and an interoperable agentic ecosystem. Danaher said the envisioned system will connect its technologies while remaining open to the broader laboratory ecosystem, helping scientists move from scientific questions to experimental evidence faster. Along with Ely Lilly and Thermo Fisher Scientific’s partnerships with Nvidia, both announced this year, Danaher’s team-up with Microsoft represents medtech’s growing intertwinement with the world’s largest tech companies.

The partnership pairs Danaher's scientific, workflow and instrumentation expertise with Microsoft's AI technologies, and will make experimental execution more streamlined and insights more readily available, according to Danaher. The platform will be built on Microsoft technology: Microsoft Azure for compliant cloud infrastructure, and Microsoft Foundry to power the AI agents that interpret results and guide instrument control. Its goal is to enable reuse and interoperability across technologies, allowing specialized products to be built on a shared foundation while remaining open to agents and digital solutions in multi-vendor laboratories.

While the companies are continuing to develop this platform, the first commercial applications will reach Danaher customers this year, including MetaXpress Acquire AI Assistant, Molecular Devices' software for its high-content cellular imaging systems, designed to provide product support. Additional next-generation, agent-enabled instruments from Danaher businesses that use this platform are planned for 2027, the company said. "With Microsoft we are building a common foundation, so our instruments and laboratories work together consistently, as one connected Danaher,” said Julie Sawyer Montgomery, president and CEO of Danaher, in a statement.

“Through context and learning, that foundation can continuously inform the next experiment and the best analysis. This partnership is an important step toward making laboratories not just connected, but intelligent." Smart, agent-enabled instruments are being designed through the partnership to translate scientific intent into experimental plans, instrument setups, and methods, control instrument hardware, interpret results and identify quality issues in real time, and recommend corrective actions and next experiments for scientist review. In preliminary internal testing data shared by Danaher, novice scientists conducting an AI-assisted experiment on a Leica microscope took up to 83% less time and up to 68% fewer steps to complete than a novice working without the AI assistant, while producing high-quality data and completing the experiment in a time comparable to an expert.

The partnership is designed to advance Danaher's broader strategy for AI and autonomous science by connecting intelligence at the instrument with data, laboratory workflows, and the physical execution of experiments. Intelligent instruments are a first step. Microsoft Danaher Corp Artificial Intelligence Diagnostics MedTech

source

Reporting by Fierce Biotech.

read at Fierce Biotech ↗
445 words · retrieved 1m ago
sharex / twitterlinkedin

comments(0)

5-min edit window · permanent after that
sign in to leave a comment · permanent archive after 5 minutes
no comments yet — first sniff?

companies & drugs in this story

no entities indexed yet

related stories

  • 1d agoFDA pushes decision on Belite’s eye disease pill back to MayFierce Biotech
  • 2d agoMerck’s TROP2 ADC extends survival in pivotal gastroesophageal cancer trialFierce Biotech
  • 2d ago‘It’s a very healthy sector’: Biopharma gathers in London as M&A shines and China clouds loomFierce Biotech
  • 2d agoBausch + Lomb and Celldex rocked by respective phase 2 flopsFierce Biotech
  • 2d agoAnthropic board director Vas Narasimhan bets AI can help Novartis solve ‘biological latency’Fierce Biotech